Inflammation and intracellular metabolism: new targets in OA  by Liu-Bryan, R.
Osteoarthritis and Cartilage 23 (2015) 1835e1842Inﬂammation and intracellular metabolism: new targets in OA
R. Liu-Bryan*
VA San Diego Healthcare System, Department of Medicine, University of California San Diego, San Diego, CA, USAa r t i c l e i n f o
Article history:
Received 12 December 2014
Accepted 17 December 2014
Keywords:
Inﬂammation
Energy metabolism
Cartilage homeostasis
AMPK
SIRT1* Address correspondence and reprint requests to: R
Jolla Village Drive, 111K, San Diego, CA 92161, USA. T
858-552-7425.
E-mail address: ruliu@ucsd.edu.
http://dx.doi.org/10.1016/j.joca.2014.12.016
1063-4584/Published by Elsevier Ltd on behalf of Osts u m m a r y
Articular cartilage degeneration is hallmark of osteoarthritis (OA). Low-grade chronic inﬂammation in
the joint can promote OA progression. Emerging evidence indicates that bioenergy sensors couple
metabolism with inﬂammation to switch physiological and clinical phenotypes. Changes in cellular
bioenergy metabolism can reprogram inﬂammatory responses, and inﬂammation can disturb cellular
energy balance and increase cell stress. AMP-activated protein kinase (AMPK) and sirtuin 1 (SIRT1) are
two critical bioenergy sensors that regulate energy balance at both cellular and whole-body levels.
Dysregulation of AMPK and SIRT1 has been implicated in diverse human diseases and aging. This review
reveals recent ﬁndings on the role of AMPK and SIRT1 in joint tissue homeostasis and OA, with a focus on
how AMPK and SIRT1 in articular chondrocytes modulate intracellular energy metabolism during stress
responses (e.g., inﬂammatory responses) and how these changes dictate speciﬁc effector functions, and
discusses translational signiﬁcance of AMPK and SIRT1 as new therapeutic targets for OA.
Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International.Introduction
Osteoarthritis (OA) is the most common form of arthritis. Aging,
obesity and biomechanical injury increase the risk of developing
OA1. The central characteristic of OA is progressive degeneration of
cartilage, which leads to permanent functional joint failure and
disability1. However, OA is a disorder of the whole synovial joint
organ1. Other joint tissues such as synovium and subchondral bone
are also affected in OA1e4. Increasing evidence indicates that low-
grade local joint inﬂammation (synovitis), induced by endoge-
nous molecular products derived from cellular stress and extra-
cellular matrix disruption acting through innate inﬂammatory
network, can inﬂuence integrity and function of articular cartilage
and promote OA progression5,6. Low-grade systemic inﬂammation
resulted from metabolic disturbance could also contribute to OA
progression7. Mounting an inﬂammatory response is an energy-
intensive process8,9. The concept of interplay between cellular
bioenergetics/metabolism and inﬂammation has been
emerged8e10. Pro-inﬂammatory mediators alter cellular energy
metabolism. Disturbances in the maintenance of cellular energy
balance trigger cell stress and induce inﬂammation8e10. Effective. Liu-Bryan, VASDHS, 3350 La
el: 1-858-552-8585; Fax: 1-
eoarthritis Research Society Internregulation of cellular energy metabolism is critical for tissue ho-
meostasis11. AMP-activated protein kinase (AMPK) and sirtuin 1
(SIRT1) are two critical energy sensors that regulate energy balance
at both cellular andwhole-body levels11. The aim of this review is to
discuss recent advancement in understanding the role of AMPK and
SIRT1 in joint tissue homeostasis and OA, and their potential to be
used as therapeutic targets in OA.
Function of AMPK and SIRT1 in articular cartilage
Articular cartilage is an avascular and hypoxic connective tis-
sue12. Chondrocytes embedded in the articular cartilage have to
cope with a nutritionally challenging environment in which
metabolic demands may change due to alterations in biomechan-
ical demands, local inﬂammatory mediators, aging and other fac-
tors12. Glucose transport and glycolysis, and less so mitochondrial
oxidative phosphorylation (OXPHOS), provide the primary sources
of metabolic energy in articular chondrocytes12,13.
AMPK in chondrocytes
AMPK, a serine/threonine kinase, is amaster regulator of cellular
energy balance, whose notable conservation in evolution supports
its fundamental role in cell biology14,15. AMPK exists in essentially
all eukaryotic cells in the form of heterotrimeric complexes
comprising catalytic a-subunits and regulatory b- and g-subunits.
Each subunit has 2e3 isoforms (a1, a2, b1, b2, g1, g2, g3) encodedational.
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threonine within the catalytic domain of both the a1 and a2 sub-
units (which are 90% homologous in their catalytic cores) is crucial
for AMPK activity14,15. Articular chondrocytes express a1, a2, b1, b2
and g1 isoforms of AMPK subunits, and a1 appears to be the pre-
dominantly expressed and functionally active AMPK a isoform16.
AMPK is activated by metabolic stress (e.g., nutrient deprivation,
hypoxia, heat shock, and exercise/muscle contraction)14,15. Once
activated, AMPK responds by phosphorylating multiple down-
stream targets, which allow inhibition of pathways that consume
ATP such as fatty acid, phospholipid, and protein biosynthesis, and
activation of pathways that generate ATP such as glucose uptake
and fatty acid oxidation14,15. In this manner, AMPK allows cells to
adjust to changes in energy demand14,15. AMPK can also be acti-
vated by pharmacological compounds such as the nucleotide
mimetic AICAR (5-aminoimidazole-4-caboxamide 1-b-D-ribofur-
anoside), and A-769662 which is a selective and direct AMPK
activator14,15.
We discovered that phosphorylation of AMPKa Thr172 (indica-
tion of AMPK activity) is constitutively present in normal articular
chondrocytes/cartilage, but is decreased in human knee OA chon-
drocytes/cartilage16, in mouse knee OA cartilage17, and in aged
mouse knee cartilage17. In addition, phosphorylation of AMPKa is
decreased, correlated with increased catabolic responses in normal
chondrocytes challenged with either inﬂammatory cytokines IL-1b
and TNFa or biomechanical injury16,17. Moreover, AMPK pharma-
cological activators are able to reverse these effects16,17. These data
suggest that sustained AMPK activity in articular chondrocytes
could be critical for cartilage matrix homeostasis.
Regulation of AMPK activity involves phosphorylation by up-
stream kinases. The liver protein kinase B1 (LKB1) is thought to be
the primary upstream kinase that phosphorylates AMPKa
Thr17214,15. This is true in articular chondrocytes, as phosphoryla-
tion of AMPKa is nearly completely inhibited in LKB1 knockdown
chondrocytes17. In addition, chondrocyte catabolic responses to IL-
1b and TNFa are signiﬁcantly enhanced in LKB1 knockdown
chondrocytes17. Interestingly, concomitant reduction of phosphor-
ylation of both LKB1 and AMPKa is observed in primary human
knee OA chondrocytes, in mouse knee OA cartilage, in aged mouse
knee cartilage, and in chondrocytes challenged with mechanical
injury17, indicating that dysregulation of LKB1 in aged and OA
cartilage may play a major role in suppression of AMPK activation.Chondrocyte  
Catabolism 
Aging, inflammation, biomechanical injury  
p-AMPK SIRT1 
p-LKB1, PP2C PTP1B
 Chondrocyte 
Anabolism 
Fig. 1. Impaired chondrocyte AMPK and SIRT1 activity disrupts cartilage matrix ho-
meostasis. Aging, inﬂammation and biomechanical injury in the joint can decrease
phosphorylation of AMPKa Thr172 (indicating AMPK activity) and expression of SIRT1
in articular chondrocytes, likely through down-regulation of activity of the major
upstream AMPK kinase LKB1 and up-regulation of protein phosphatase PP2Ca, and
PTB1B. As a result, the balance between chondrocyte catabolic and anabolic function is
disrupted. Overactive chondrocyte catabolic responses ultimately lead to cartilage
matrix degradation.AMPK activity, on the other hand, can be negatively regulated
through de-phosphorylation by protein phosphatases such as
protein phosphatase 2A (PP2A) and PP2Ca14,15. We found that
phosphorylation of AMPKa (Thr172) was increased, while catabolic
responses were decreased in the PP2Ca knockdown chondrocytes
stimulated with IL-1b and TNFa (unpublished observation). Thus,
chondrocytes with reduced AMPK activity are more susceptible to
inﬂammation-induced catabolic responses (Fig. 1).
SIRT1 in chondrocytes
SIRT1, another evolutionary conserved energy sensor, is a
member of sirtuins that are nicotinamide adenine dinucleotide
(NADþ)-dependent lysine deacetylases, acting on a wide range of
protein substrates11,18,19. Expression of SIRT1 is decreased in both
human andmouse knee OA cartilage, as well as in agedmouse knee
cartilages20e22. Inhibition of SIRT1 in chondrocytes leads to
increased apoptosis and enhanced pro-catabolic responses to IL-1b
and TNFa23e25. Moreover, SIRT1 promotes cartilage-speciﬁc gene
expression26, protects chondrocytes from radiation-induced
senescence27, and inhibits apoptosis in chondrocytes23,28,29. SIRT1
enhances human OA chondrocyte survival by repressing protein
tyrosine phosphatase 1B (PTP1B), a potent pro-apoptotic protein23.
Furthermore, adult heterozygous Sirt1 knockout (KO) mice and
mice with a Sirt1 point mutation exhibit increased OA progres-
sion29,30, and cartilage-speciﬁc Sirt1 KO mice develop accelerated
OA progression22. Clearly, SIRT1 has a chondroprotective role.
AMPK and SIRT1 in chondrocyte stress resistance
Activation of AMPK is shown to stimulate the functional activity
of SIRT1 by increasing the intracellular concentrations of NADþ in
several different cell types11,31. SIRT1 deacetylates LKB1, which
subsequently increase LKB1 activity, leading to AMPK activa-
tion11,31. The same scenario was seen in articular chondrocytes as
well (unpublished observation). This positive feedback loop be-
tween SIRT1 and AMPK could potentiate the function of AMPK, and
effectively control cellular energy balance11,31. Importantly, AMPK
and SIRT1 not only regulate cellular energy metabolism, but also
coordinate several housekeeping mechanisms to increase cell
stress resistance via certain downstream mediators.
Regulation of mitochondrial biogenesis and function
AMPK phosphorylates PGC-1a (peroxisome proliferator-
activated receptor g co-activator 1a) protein that subsequently al-
lows SIRT1 to deacetylate and activate PGC-1a11,31. PGC-1a, a
transcriptional co-activator, is a master regulator of mitochondrial
biogenesis and function11,31. The primary function of mitochondria
is to produce ATP through the process of OXPHOS, transduced by
the respiratory complexes (IeIV) and the ATP synthase (complex
V)13,32. Mitochondrial function is known to decline with aging33. As
cells age, the efﬁcacy of the mitochondrial respiratory chain tends
to diminish, thus increasing electron leakage that leads to increases
in reactive oxygen species (ROS) production and oxidative damage,
and reduced ATP generation33. Mitochondrial function is impaired
in OA chondrocytes, reﬂected by decreased numbers of mitochon-
dria and activity of respiratory complexes I, II and III13,32,34.
Although the majority of the ATP in chondrocytes is made by
glycolysis rather than by OXPHOS, ATP levels per chondrocyte are
reduced despite glycolysis is increased in OA chondrocytes35, which
not only contributes to decreased mitochondrial bioenergetic
reserve36e38, but also adversely affects cellular redox balance39e42,
and chondrocyte homeostatic functions dependent on physiolog-
ical generation of low levels of ROS41,42.
Fig. 2. The UPR in articular chondrocytes in OA. ER stress in OA chondrocytes caused
by certain inﬂammatory mediators, biomechanical injury, nitric oxide and AGEs leads
to activation of the UPR signaling cascades triggered by dissociation of the chaperon
GRP78 from the ER transmembrane proteins PERK, IRE1a, and ATF6. The active XBP1
spliced form (XBP1s), generated by IRE1a through alternatively splicing mRNA of
unspliced XBP1 (XBP1u), promotes chondrocyte hypertrophy and increases catabolic
responses. The cleaved active form of ATF6 (p50) can induce XBP1 expression through
direct binding to XBP1 promoter. Increased CHOP expression potentiates IL-1b to
decrease phosphorylation of AMPKa and induce catabolic responses, superoxide
generation and apoptosis.
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sion of cartilage degradation. It increases responsiveness of chon-
drocytes to pro-inﬂammatory cytokines, leading to increased
matrix catabolism43,44. Mitochondrial biogenesis is important for
maintenance of mitochondrial function. We recently found that
expression of PGC-1a is decreased in both mouse knee OA cartilage
and in aged mouse knee cartilage45. In addition, we observed that
mitochondrial biogenesis capacity and function are signiﬁcantly
reduced in advanced human knee OA chondrocytes, indicated by
deceased mitochondrial DNA content and mitochondrial mass, and
reduced oxygen consumption rate and intracellular ATP level, all of
which were correlated with concomitant reduction of phosphory-
lation of AMPKa, expression of SIRT1 and PGC-1a, and increased
acetylation of PGC-1a (unpublished observation). Moreover, the
established impairments in mitochondrial biogenesis and function
in advanced human knee OA chondrocytes can be reversed by
either AMPK pharmacologic activation or overexpression of SIRT1
or PGC-1a (unpublished observation).
Inhibition of oxidative stress and inﬂammatory responses
FOXO3a, a transcription factor that belongs to the forkhead box
O (FOXO) family, is another downstream target of AMPK and
SIRT111,31. As for PGC-1a, AMPK directly phosphorylates FOXO3a,
and SIRT1 deacetylates and activates FOXO3a11,31. PGC-1a and
FOXO3a are closely related. FOXO3a is a direct transcriptional
regulator of PGC-1a, and PGC-1a itself can augment the tran-
scriptional activity of FOXO3a46. Both PGC-1a and FOXO3a have
been shown to limit cellular oxidative stress by up-regulating
antioxidant enzymes, including manganese superoxide dismutase
(MnSOD or SOD2) and catalase46,47. In this light, reduction of SOD2
expression has been linked to chondrocyte mitochondrial
dysfunction48 and OA progression49. Similar to PGC-1a, expression
of FOXO3a is reduced in both mouse knee OA cartilage and in aged
mouse knee cartilage45. AMPK pharmacologic activation enhances
expression of PGC-1a and FOXO3a, as well as SOD2 and catalase,
and inhibits oxidative stress in articular chondrocytes45.
Mitochondria dysfunction leads to elevated levels of ROS, which
promotes cartilage degradation directly by cleaving collagen and
aggrecan and indirectly by activating matrix metalloproteinases
(MMPs)50,51. Additionally, ROS act indirectly by modulating redox-
sensitive NF-kB and other signaling pathways that increase chon-
drocyte catabolic activity41,42,52. NF-kB plays a major role in innate
immune responses. The regulation of innate immunity and energy
metabolism is connected together through an antagonistic cross-
talk between NF-kB and AMPK and SIRT1 signaling pathways11,53,54.
Many studies have demonstrated that activities of AMPK and SIRT1
have anti-inﬂammatory effects in diverse types of cells and tis-
sues11,31. Activation of AMPK inhibits NF-kB activation via SIRT1,
which deacetylates p65 NF-kB subunit, ultimately primes p65 for
proteasome degradation11,31. Studies have shown that activation of
AMPK or SIRT1 inhibits pro-inﬂammatory responses to IL-1b and
TNFa via attenuation of NF-kB activation in articular
chondrocytes16,24,25,55e57. In addition, PGC-1a and FOXO3a, at least
in part, mediate AMPK to inhibit NF-kB activation and inﬂamma-
tory cytokine-induced catabolic responses in chondrocytes45. In-
ﬂammatory cytokines have negative impact on both
phosphorylation of AMPKa and SIRT1 expression in chon-
drocytes16,26. IL-1b and TNFa de-phosphorylate AMPKa partially by
inducing increased expression of PP2Ca (unpublished observation).
TNFa also reduces SIRT1 activity in chondrocytes by inducing
cathepsin B-mediated cleavage of SIRT158. In addition, activation of
NF-kB can down-regulate SIRT1 activity through induction of
expression of miR-34a, which targets the 30 UTR of SIRT1 and in-
hibits the expression of SIRT159. Chondrocytes with reducedactivity of AMPK or SIRT1 have increased responsiveness to in-
ﬂammatory cytokines16,25. These ﬁndings suggest that chronic low-
grade inﬂammation in OA and aging joint could be associated with
dysregulation of AMPK and SIRT1 signaling, which reduces chon-
drocyte resistance to inﬂammatory stress and further provokes
inﬂammatory responses.
Modulation of endoplasmic reticulum (ER) stress
The ER is a sub-cellular organelle where all secretory and inte-
gral membrane proteins are folded and post-translationally modi-
ﬁed. The ER is also a site of calcium storage and lipid biosynthesis.
Protein folding in the oxidizing environment of the ER is an energy-
requiring process60,61. Stresses that compromise the ER homeo-
stasis such as perturbations in calcium homeostasis, energy stores,
redox state, and metabolic and inﬂammatory challenges result in
the accumulation of misfolded proteins and activation of a stress
response termed the unfolded protein response (UPR)60,61. Several
adaptive signaling pathways have evolved to restore an efﬁcient
protein-folding environment through the induction of chaperones,
degradation of misfolded proteins and attenuation of protein
translation60,61. Inositol-requiring kinase 1 (IRE1), ER eukaryotic
translation initiation factor 2 (eIF2a) kinase (PERK), and activating
transcription factor 6 (ATF6) are the three branches of UPR
signaling cascade, which are triggered by disassociation of the
chaperon GRP78 upon ER stress60,61. When ER stress is too severe or
chronic, or the UPR is unable to resolve the protein-folding defects,
cells are led to apoptosis through induction of C/EBP homologous
protein (CHOP)60,61.
The UPR is activated in OA articular chondrocytes (Fig. 2), evi-
denced by increased expression of GRP78 and CHOP, as well as
generation of alternatively spliced and transcriptionally activated
X-box protein 1 (XBP1) in OA cartilage62,63. ATF6 upregulates XBP1
expression in OA chondrocytes by promoting direct binding to
XBP1 promoter64, and increased XBP1s expression accelerates
chondrocyte hypertrophy65. XBP1 expression is also increased by
IL-1b in chondrocytes62. Inhibition of XBP1 expression in
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induced by IL-1b62. Several factors implicated in OA pathogenesis
including biomechanical injury, IL-1b, nitric oxide and advanced
glycation end products (AGEs) upregulate expression of GRP78 and
CHOP in cultured articular chondrocytes62,63,66e69. CHOP potenti-
ates the capacity of IL-1b to induce catabolic responses, superoxide
generation and apoptosis in chondrocytes, and does so by inhibit-
ing AMPK activity62. Moreover, CHOP-mediated apoptosis con-
tributes to the progression of cartilage degeneration in mice70.
Moreover, pharmacologic AMPK activation blunts CHOP expression
and catabolic responses induced by IL-1b and biomechanical
injury17,62. These data indicate that AMPK modulates UPR, and
activation of AMPK alleviates ER stress in chondrocytes.
Regulation of autophagy
Autophagy is a cellular housekeeping and protein quality con-
trol mechanism, which can remove damaged or defective proteins
and organelles, e.g., damaged mitochondria11,71. AMPK controls
autophagy through mammalian target of rapamycin (mTOR) and
Unc-51-like kinase 1 (ULK1) signaling71. mTOR, a conserved Ser/Thr
protein kinase, is a potent inhibitor of autophagy. ULK1 is a critical
kinase that governs the cascade of events triggering autophagy.
AMPK can inhibit activity of mTOR complex (mTORC1) either by
directly phosphorylating Raptor, a regulatory component of
mTORC1, or by phosphorylating tuberous sclerosis protein 2 (TSC2),
which subsequently suppresses mTOR activity71. AMPK stimulates
autophagy by dissociating mTORC1 from the ULK1 complex via the
phosphorylation of the Raptor component, as well as by directly
binding to the ULK1 complex and phosphorylating ULK171. In
addition, AMPK can also enhance the later steps in autophagosome
formation through SIRT1 by deacetylating several autophagy-
related proteins (e.g., Atg5, Atg7 and Atg8)11. Chondrocyte auto-
phagy is known to be a constitutive homeostatic mechanism in
articular cartilage72, which can be promoted by AMPK signaling73,74
through mTOR suppression. As for both phosphorylation of AMPKa
and SIRT1 expression, chondrocyte autophagy is reduced with a
linked increase in apoptosis in human knee OA, mouse knee OA and
aged mouse knee cartilages75. Suppressed autophagy also is
observed in cartilage ex vivo in response to mechanical injury76.
Inhibition of autophagy in chondrocyte exacerbated IL-1beinduced
OA-like gene expression changes and apoptotic signals, while
activation of autophagy inhibited them, possibly through modula-
tion of ROS in chondrocytes in vitro77. Cartilage-speciﬁc genetic
deletion of mTOR78 and pharmacologic inhibition of mTOR
signaling by rapamycin79 upregulates autophagy and reduces the
severity of experimental OA in vivo.
Function of AMPK and SIRT1 in synovium and bone
The function of bioenergy sensors in synovium is merely studied
yet. One study using ﬁbroblast-like synoviocytes (FLS) of rheuma-
toid arthritis (RA) showed that SIRT1 expression is decreased by
HMGB1, but is recovered by pre-treatment with resveratrol, a SIRT1
activator80. Interestingly, Cilostazol, a drug used to treat intermit-
tent claudication that has been shown to activate AMPK, prevents
HMGB1-induced angiogenesis via SIRT1 in RA FLS in vitro and ex-
hibits anti-angiogenic effect in collagen-induced arthritis (CIA)
mouse model in vivo80. Simvastatin, a cholesterol-lowering drug
that is also known to activate AMPK, inhibits cysteine-rich angio-
genic inducer 61 (CYR61) and CCL20 in RA FLS via up-regulation of
SIRT1/FOXO3a signaling81. These results implicate an anti-
inﬂammatory role of synovial activation of AMPK and SIRT1.
Whether activation of AMPK and SIRT1 limits synovial inﬂamma-
tion in OA needs to be investigated.Both AMPK and SIRT1 are involved in regulation of bone
metabolism. Activation of AMPK promotes osteoblast differentia-
tion, bone formation and bone mass, and inhibits osteoclast dif-
ferentiation in vitro82e91. Mice deﬁcient in AMPKa1 or AMPKa2
exhibit reduced bone mass compared with WT mice83. AMPKa1
deﬁcient mice have an elevated rate of bone remodeling, whereas
AMPKa2 deﬁcient mice largely have elevated bone resorption83.
Osteoclast- or osteoblast-speciﬁc SIRT1 conditional KO mice have
decreased bone mass caused by increased resorption and reduced
bone formation90. Wnt/b-catenin is known to be indispensable for
osteoblast generation. SIRT1 is shown to regulate differentiation of
mesenchymal stem cells (MSCs) by deacetylating b-catenin92. MSCs
isolated from MSC-speciﬁc SIRT1 KO mice have reduced differen-
tiation towards osteoblasts and chondrocytes in vitro92. Activation
of AMPK or SIRT1 decreases adipocyte and promotes osteoblast
formation during differentiation of MSCs93e95, suggesting a critical
role of AMPK and SIRT1 in regulation of the lineage commitment of
MSCs. Osteoprogenitor-speciﬁc SIRT1 KO mice display lower
cortical thickness in femora and vertebrae because of reduced bone
formation at the endocortical surface, associated with decreased
Wnt/b-catenin signaling88. Decreased expression of SIRT1 is found
in human OA subchondral bone osteoblasts89. Inhibition of SIRT1 in
osteoblasts leads to abnormal sclerostin expression that decreases
Wnt/b-catenin activity89, which can be inhibited by resveratrol89.
Obviously, AMPK and SIRT1 play an important role in bone ho-
meostasis. Abnormal AMPK and SIRT1 levels in osteoblasts and
osteoclasts may contribute to subchondral bone pathological
changes in OA.
Clinical relevance and translation
Dysregulation of AMPK and SIRT1 is linked to diabetes,
atherosclerosis, cardiovascular disease, cancer, neurodegenerative
diseases11,33, as well as OA based on recent ﬁndings, all of which are
age-related diseases. Studies have revealed that responsiveness of
AMPK activation declines during the aging process11, and low-grade
inﬂammation present in aging tissues may be at least in part
responsible for suppressing AMPK signaling11. The prevalence of OA
increases with aging further supports the concept that a dysfunc-
tion of AMPK is involved in the disease process.
Nutritional factors can affect AMPK signaling. Caloric restriction
is known to stimulate AMPK activity, whereas nutritional overload
seems to impair AMPK activity, which can induce insulin resistance
in many tissues11. The metabolic disturbance can cause low-grade
inﬂammation leading to development of metabolic syndrome
such as obesity and diabetes11, which are often associated with OA7.
Diet rich in n-3 long chain polyunsaturated fatty acids (PUFAs) is
considered as a nutritional tool to prevent insulin resistance asso-
ciated to type 2 diabetes and obesity96. This is probably at least in
part owing to the ability of n-3 PUFAs to stimulate AMPK
activity97e100. Exercise is considered as one of the most cost
effective approaches to provide health beneﬁts101. Evidence sup-
ports beneﬁts of various types of exercise for improving pain and
function in knee OA102. Studies in both animals and humans
demonstrate that skeletal muscle contraction and exercise activate
AMPK in an intensity and time-dependent manner101,103, and
increased AMPK activation promotes adaptation to muscle endur-
ance exercise101,103. As such, activation of AMPK provides molecular
basis of the beneﬁts of exercise, and supports clinical recommen-
dation of exercise for the management of OA102.
A number of drugs already in the clinic for arthritis and other
conditions (e.g., sodium salicylate, high dose aspirin, methotrexate,
metformin), and a variety of natural plant products either present
in traditional medicine or derived from food (e.g., berberine,
resveratrol, curcumin, quercetin) appealed to have “nutraceutical”
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of themwere in use for their respective purposes before they were
known to be activators of AMPK104,105. Interestingly, a recent study
on a randomized placebo-controlled small trial of methotrexate in
symptomatic knee OA showed signiﬁcant improvement in physical
function associated with reduced pain and synovitis106. In addition,
a randomized double-blind placebo-controlled small trial of cur-
cuminoid (closely related to curcumin) in treatment of knee OA also
showed signiﬁcant improvements in pain and physical function107.
Moreover, several randomized placebo-controlled trials of avoca-
doesoybean unsaponiﬁables (ASU) on both knee and hip OA
demonstrated signiﬁcant efﬁcacy in improving the symptoms of OA
and reducing progression of joint space narrowing108e110. ASU is a
natural vegetable extract made from avocado and soybean oils used
as a dietary supplement. The carotenoids such as b-carotene and
lutein present in avocado, and a key isoﬂavone genistein present in
soybean are capable of activating AMPK111e113. The beneﬁcial ef-
fects of the agents tested in the OA clinical trails aforementioned
are conceivably in part due to AMPK activation, which warrant
further investigation.Conclusion
Disturbances in the maintenance of energy balance provoke
diseases and jeopardize healthy aging11. Reduced capacity of AMPK
and SIRT1 activation in articular joint tissues could limit energy
availability for cellular maintenance, trigger signiﬁcant cell stress
by inducing mitochondrial dysfunction, oxidative stress and
inﬂammation, ultimately, compromise cell survival and tissue
function. These bioenergy sensors can couple metabolism with
inﬂammation to switch physiologic and clinical phenotypes. Given
the fact that activation of AMPK and SIRT1 in articular chondrocytes
regulates energy balance and coordinates several housekeeping
mechanisms to increase cell stress resistance and maintain quality
control (Fig. 3), targeted activation of AMPK and SIRT1 appeals to be
an attractive therapeutic strategy for OA, which could be potentiallyAMPK 
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Fig. 3. AMPK and SIRT1 activity in regulation of cartilage homeostasis by increasing
chondrocyte stress resistance. Pharmacological activators (e.g., AICAR, A-769662, and
metformin), possibly some natural plant products (nutraceuticals), caloric restriction
and exercise, activate AMPK in articular chondrocytes. As a result, intracellular NADþ
level is increased, leading to activation of SIRT1. Resveratrol, a natural plant product,
also activates SIRT1. In turn, SIRT1 activates LKB1, the major upstream kinase of AMPK,
through deacetylation of LKB1. Activation of AMPK and SIRT1 coordinates several
housekeeping mechanisms to increase chondrocyte stress resistance by increasing
mitochondrial biogenesis and function via PGC-1a; inhibiting oxidative stress and via
PGC-1a and FOXO3a; attenuating inﬂammatory responses via inhibition of NF-kB
activation, alleviating ER stress via limiting excessive CHOP; and promoting autophagy
via suppression of mTOR, ultimately leading to cartilage homeostasis.achieved by pharmacologics, lifestyle measures (diet and exercise)
and nutraceuticals.
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